Skip to Content
Sep 21 2022
Recommended phase 2 dose established at 33% of gross tumor volume in all three cohorts from the complete escalation part of Study 1100 Updated clinical data from Study 1100 expected in Q4 2022 Submission of protocol to United States Food and Drug Administration for Phase 3 clinical trial evaluating
Sep 08 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Sep. 8, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext
Aug 09 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Aug. 9, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext
Jul 08 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Jul. 8, 2022-- Regulatory News : Nanobiotix (Paris:NANO)(NASDAQ:NBTX) Market: Euronext Paris